Preclinical pharmacology of TAK-147, a novel acetylcholinesterase inhibitor, as a potential therapeutic drug of Alzheimer's disease

CNS Drug Reviews

Volumn 3, Issue 4, 1997, Pages 301-324

  Miyamoto, Masaomi ^a   Goto, Giichi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Acetylcholinesterase inhibitor; Aged rats; Alzheimer's disease; Behavioral depression; Butylcholinesterase; CNS selectivity; Donepezil; Learning and memory; Tacrine; TAK 147

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; TACRINE; ZANEPEZIL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG MECHANISM; LEARNING; MEMORY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0031395649     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1997.tb00330.x     Document Type: Article

References (83)

1. Aigner T, Mitchell SJ, Aggleton JP, et al. Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 1987;92:292-300.
2. Askew BM. A simple screening procedure for imipramine-like antidepressant agents. Life Sci 1963;10:725-730.
3. Barnes CA, Nadel L, Honig WK. Spatial memory deficit in senescent rats. Can J Psychol 1980;34:29-39.
4. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-417.
5. Berger-Sweeney J, Heckers S, Mesulam M-M, et al. Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J Neurosci 1994;14:4507-4519.
6. Biesold D, Inanami O, Sato A, Sato Y. Stimulation of the nucleus basalis of Meynert increases cerebral cortical blood flow in rats. Neurosci Lett 1989;98:39-44.
7. Blass JP. Pathophysiology of the Alzheimer syndrome. Neurology 1993;43:528-538.
8. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurobiology 1982;32:164-168.
9. Christie JE, Shering A, Ferguson J, Glen AIM. Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981;138:46-50.
10. Clarke RPF, Eccersley PS, Frisby JP, Thornton JA. The amnesic effect of diazepam (Valium). Br J Anaesth 1970;42:690-697.
11. Cole SO. Effects of benzodiazepines on acquisition and performance: A critical assessment. Neurosci Biobehav Rev 1986;10:265-272.
12. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
13. Curcio CA, Kemper T. Nucleus raphe dorsalis in dementia of the Alzheimer type: Neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 1984;43:359-368.
14. Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982;139:1421-1424.
15. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
16. Davis P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1977;ii:1403.
17. Dawson GR, Iversen SD. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 1993;57:143-153.
18. Decker AJ, Winkler J, Ray J, et al. Grafting of nerve growth factor-producing fibroblasts reduces behavioral deficits in rats with lesions of the nucleus basalis magnocellularis. Neuroscience 1994;60:299-309.
19. De Leon MJ, Harris SH, George AE, et al. Computed tomography and positron emission transaxial tomography evaluation of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab 1983;3:391-394.
20. Drachman DA. Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 1977;27:783-790.
21. Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986;36:879-887.
22. Dunnett SB. Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology 1985;87:357-363.
23. Edvinsson L, Falck B, Owman C. Possibilities for a cholinergic activation on smooth musculature and on sympathetic axons in brain vessels mediated by muscarinic and nicotinic receptors. J Pharmacol Exp Ther 1977;200:117-126.
24. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:253-2529.
25. Fischer W, Wictorin K, Björklund A, et al. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987;329:65-68.
26. Gage FH, Dunnett SB, Björklund A. Spatial learning and motor deficits in aged rats. Neurobiol Aging 1984;5:43-48.
27. Fujimoto K. Morphology of cerebrovascular autonomie innervation. Adv Neural Sci 1988;32:194-210.
28. Gallagher M, Pelleymounter MA. Spatial learning deficits in old rats: A model for memory decline in the aged. Neurobiol Aging 1988;9:549-556.
29. Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: A review. Anesthesiology 1990;72:926-938.
30. Giacobini E, Zhu X-D, Williams E, Sherman KA. The effect of selective acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996;35:204-211.
31. Gomi S, Gotoh F, Ishihara N, et al. Effects of lesioning of the substantia innominata on autoregulation of local cerebral blood flow in rats. J Cereb Blood Flow Metab 1991;11:66-71.
32. Gottfries CG. Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment. Psychopharmacology 1985;86:245.
33. Grady CL, Grimes AM, Patronas N, et al. Divided attention, as measured by dichotic speech performance in dementia of the Alzheimer type. Arch Neurol 1989;46:317-320.
34. Haxby JV, Grady CL, Duara R, et al. Neocortical metabolic abnormalities precede nonmemory cognitive deficits in early Alzheimer-type dementia. Arch Neurol 1986;43:882-885.
35. Heikkila RE. Differential effects of several dopamine uptake inhibitors and releasing agents on locomotor activity in normal and in reserpinized mice. Life Sci 1981;28:1867-1873.
36. Heistad DD, Marcus ML, Said SI, Gross PM. Effect of acetylcholine and vasoactive intestinal peptide on cerebral blood flow. Am J Physiol 1980;239:H73-H80.
37. Hirai K, Kato K, Nakayama T, et al. Neurochemical effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- 1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats. J Pharmacol Exp Ther 1997;280:1261-1269.
38. Hodges H, Green S. Effects of chlordiazepoxide on cued radial maze performance in rats. Psychopharmacology 1986;88:460-466.
39. Ishihara Y, Hirai K, Miyamoto M, Goto G. Central cholinergic agents. 6. Synthesis and evaluation of 3[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1- propanones and their analogs as central selective acetylcholinesterase inhibitors. J Med Chem 1994;37:2292-2299.
40. Jarrard LE, Kant GJ, Meyerhoff JL, Levy A. Behavioral and neurochemical effects of intraventricular AF64A administration in rats. Pharmacol Biochem Behav 1984;21:272-280.
41. Katzman R. Alzheimer's disease. N Engl J Med 1986;315:964-973.
42. Kawashima K, Sato A, Yoshizawa M, et al. Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmiedeberg's Arch Pharmacol 1994;350:523-528.
43. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
44. Malin DH, Plotner RE, Radulescu SJ, et al. Chronic methanesulfonyl fluoride enhances one-trial per day reward learning in aged rats. Neurobiol Aging 1993;14:393-395.
45. Mann DM, Yates PO, Marcyniuk B. A comparison of change in the nucleus basalis and locus coeruleus in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1984;47:201-203.
46. Martinez-Serrano A, Fischer W, Björklund A. Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neuronal progenitors grafted to the basal forebrain. Neuron 1995;15:473-484.
47. Meneilly GS, Hill A. Alterations in glucose metabolism in patients with Alzheimer's disease. J Am Geriat Soc 1993;41:710-714.
48. Mielke R, Herholz K, Ground M, et al. Clinical deterioration in probable metabolic impairment of association areas. Dementia 1994;5:36-41.
49. Miyamoto M, Hirai K, Takahashi H, et al. Effects of sustained release formulation of thyrotropin-releasing hormone on learning impairments caused by scopolamine and AF64A in rodents. Eur J Pharmacol 1993;238:181-189.
50. Miyamoto M, Kato J, Narumi S, Nagaoka A. Characteristics of memory impairment following lesioning of the basal forebrain and medial septal nucleus in rats. Brain Res 1987;419:19-31.
51. Miyamoto M, Narumi S, Nagaoka A, Coyle JT. Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. J Pharmacol Exp Ther 1989;248:825-835.
52. Miyamoto M, Shintani M, Nagaoka A, Nagawa Y. Lesioning of the basal forebrain leads to memory impairments in passive and active avoidance tasks. Brain Res 1985;328:97-104.
53. Miyamoto M, Takahashi H, Kato K, et al. Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- 1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models. J Pharmacol Exp Ther 1996;277:1261-1269.
54. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985;142:28-33.
55. Murray CL, Fibiger HC. Learning and memory deficits after lesions of the nucleus basalis magnocellularis: Reversal by physostigmine. Neuroscience 1985;14:1025-1032.
56. Murray CL, Fibiger HC. Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis of magnocellularis. Behav Neurosci 1986;100:23-32.
57. Nakayama T, Takahashi H, Miyamoto M, et al. Effects of TAK-147, a novel AChE inhibitor, on cerebral energy metabolism. Neurobiol Aging 1996;17:849-857.
58. Page KJ, Everitt BJ, Robbins TW, et al. Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: Differential dependence on cholinergic neuronal loss. Neuroscience 1991;43:457-472.
59. Pancrazi-Boyer MP, Arnaud-Castiglioni R, Michel B, Azorin JM. Tetraaminotacrine treatment and depression. Alzheimer Res 1997;3:115-117.
60. Parasuraman R, Martin A. Cognition in Alzheimer's disease: Disorders of attention and semantic knowledge. Curr Opin Neurobiol 1994;4:237-244.
61. Perry EK, Curtis M, Pick DJ. Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985:48:413-421.
62. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores. Br Med J 1978;2:1457-1159.
63. Peters BH, Levin HS. Effects of physostigmine and lecithin on memory in Alzheimer's disease. Ann Neural 1979;6:219-221.
64. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn 1977;229:327-336.
65. Price DL, Borchelt DR, Sisodia SS. Alzheimer disease and the prion disorders amyloid β-protein and prion protein amyloidoses. Proc Natl Acad Sci USA 1993;90:6381-6384.
66. Robbins TW, Everitt BJ, Ryan CN, et al. Comparative effects of quisqualic and ibotenic acid-induced lesions of the substantia innominata and globus pallidus on the acquisition of a conditional visual discrimination: Differential effects on cholinergic mechanisms. Neuroscience 1989;28:337-352.
67. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
68. Sahakian BJ, Owen AM, Morant NJ, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: Assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 1993;110:395-401.
69. Sahgal A. Contrasting effects of vasopressin, desglycinamide-vasopressin and amphetamine on a delayed matching to position task in rats. Psychopharmacology 1987;93:243-249.
70. Scinto LFM, Daffner KR, Castro L, et al. Impairment of spatially directed attention in patients with probable Alzheimer's disease as measured by eye movement. Arch Neurol 1994;51:682-688.
71. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Ann Rev Neurosci 1994;17:489-517.
72. Siegel BV Jr, Buchsbaum MS, Starr A, et al. Glucose metabolic rate and progression of illness in Alzheimer's disease. Int J Geriatr Psychiatry 1995;10:659-667.
73. Sitaram N, Weingartner H, Gillin JC. Human serial learning: Enhancement with arecoline and impairment with scopolamine. Science 1978;201:274-276.
74. Skoog I. The prevalence of psychotic, depressive and anxiety syndromes in demented and non-demented 85-year-olds. Int J Geriatr Psychiatry 1993;8:247-253.
75. Sulser F, Watts J, Brodie BB. On the mechanism of antidepressant action of imipramine-like drugs. Ann NY Acad Sci 1962;98:279-288.
76. Szelies B, Mielke R, Ground M, Heiss W-D. P 300 in Alzheimer's disease: Relationships to dementia severity and glucose metabolism. J Neurol Sci 1995;130:77-81.
77. Tan S, Kirk RC, Abraham WC, McNaughton N. Chlordiazepoxide reduces discriminability but not rate of forgetting in delayed conditional discrimination. Psychopharmacology 1990;101:550-554.
78. Thiebot MH. Some evidence for amnesic-like effects of benzodiazepines in animals. Neurosci Biobehav Rev 1985;9:95-100.
79. Tueth MJ. How to manage depression and psychosis in Alzheimer's disease. Geriatrics 1995;50:43-49.
80. Vida S, Des Rosiers P, Carrier L, Gauthier S. Prevalence of depression in Alzheimer's disease and validity of research diagnostic criteria. J Geriatr Psychiatry Neurol 1994;7:238-244.
81. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
82. Yamamoto T, Hirano A. Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large neurons. Ann Neurol 1985;17:573-577.
83. Yamazaki N, Kato K, Kurihara E, Nagaoka A. Cholinergic drugs reverse AF64A-induced impairment of passive avoidance learning in rats. Psychopharmacology 1991;103:215-222.